XTL Bio to acquire Psyga Bio, adding psychedelic manufacturing capability
read at Endpoints ↗DealNeutral
XTL Bio announced it will acquire all outstanding shares of Psyga Bio, a biotech focused on psychedelic therapies.
The transaction gives XTL access to Psyga’s manufacturing facility, expanding its capability to produce psychedelic compounds.
The move underscores growing interest in psychedelic drug development and could strengthen XTL’s pipeline.
In related news, contract manufacturing firm WuXi AppTec reported a rise in first‑quarter revenue, indicating continued demand for its services.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise”
read at Endpoints ↗78 words · retrieved Apr 30
comments(0)
5-min edit window · permanent after that